1. acute bleeding. 2. thrombolytic treatment and anticoagulant treatment at therapeutic doses. 3. pregnancy or lactation. 4. patients with active malignant tumour, other serious systemic or neuropsychiatric diseases. 5. patients participating in other clinical trials in the last month. 6. inability to give informed consent or to accomplish the requirements of the diagnostic tests. 7. patients with hypersensitivity to defibrotide.

1. acute bleeding. 2. thrombolytic treatment and anticoagulant treatment at therapeutic doses. 3. pregnancy or lactation. 4. patients with active malignant tumour, other serious systemic or neuropsychiatric diseases. 5. patients participating in other clinical trials in the last month. 6. inability to give informed consent or to accomplish the requirements of the diagnostic tests. 7. patients with hypersensitivity to defibrotide.

acute bleeding. thrombolytic treatment and anticoagulant treatment at therapeutic doses. pregnancy or lactation. patients with active malignant tumour, other serious systemic or neuropsychiatric diseases. patients participating in other clinical trials in the last month. inability to give informed consent or to accomplish the requirements of the diagnostic tests. patients with hypersensitivity to defibrotide.

acute bleeding. thrombolytic treatment and anticoagulant treatment at therapeutic doses. pregnancy or lactation. patients with active malignant tumour, other serious systemic or neuropsychiatric diseases. patients participating in other clinical trials in the last month. inability to give informed consent or to accomplish the requirements of the diagnostic tests. patients with hypersensitivity to defibrotide.

levels of il-6 ≥ 3 times the upper limit of normality

levels of il-6 ≥ 3 times the upper limit of normality

1. acute bleeding. 2. thrombolytic treatment and anticoagulant treatment at therapeutic doses. 3. pregnancy or lactation. 4. patients with active malignant tumour, other serious systemic or neuropsychiatric diseases. 5. patients participating in other clinical trials in the last month. 6. inability to give informed consent or to accomplish the requirements of the diagnostic tests. 7. patients with hypersensitivity to defibrotide.

1. acute bleeding. 2. thrombolytic treatment and anticoagulant treatment at therapeutic doses. 3. pregnancy or lactation. 4. patients with active malignant tumour, other serious systemic or neuropsychiatric diseases. 5. patients participating in other clinical trials in the last month. 6. inability to give informed consent or to accomplish the requirements of the diagnostic tests. 7. patients with hypersensitivity to defibrotide.